Abstract
Background: Chronic kidney disease (CKD) often progresses to end-stage renal disease (ESRD), severely affecting patients' lives.
Objectives: This article explored the effects of hemodialysis (HD) combined with hemoperfusion (HP) on metabolic indicators, inflammatory cytokines, and novel biomarkers—including oxidative stress markers (malondialdehyde, MDA; superoxide dismutase, SOD), vascular endothelial markers (endothelin-1, ET-1), fibrosis markers (transforming growth factor-beta1, TGF-β1), and metabolic risk markers (homocysteine, Hcy)—in CKD patients.
Methods: A retrospective analysis was conducted on clinical data from 72 CKD patients admitted to Changxing County Hospital of Traditional Chinese Medicine from October 2023 to October 2025. Patients were divided into HD+HP group (AG, n=35) and HD group (BG, n=37). Changes in metabolic indicators, inflammatory factors, and novel biomarkers before and after 6 months of treatment were compared.
Results: After treatment, the AG showed markedly lower levels of BUN, Scr, iPTH, and β₂-MG compared to the BG (P < 0.05), with a 42.3% reduction in iPTH (326.7 ± 58.4 pg/mL vs. 566.2 ± 89.1 pg/mL). The AG also had markedly lower levels of IL-6, TNF-α, and hs-CRP (P < 0.01). Novel biomarkers including MDA, ET-1, TGF-β1, and Hcy were significantly lower in AG post-treatment (P < 0.05), with SOD activity significantly increased. No visible distinction was noted in adverse event rates (P > 0.05).
Conclusion: HD combined with HP can more effectively remove medium and large molecular toxins, improve oxidative stress, endothelial function, and fibrosis markers, and markedly improve calcium-phosphorus metabolism disorders and micro-inflammatory status, providing comprehensive clinical evidence for optimizing blood purification strategies.
Keywords
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.